Administration of sesamol improved blood-brain barrier function in streptozotocin-induced diabetic rats
If you prefer a glossier lip look, swap the matte lipstick for the LOral Paris Colour Riche Satin Lipstick in Le Rouge Paris and top it off with a swipe of the LOral Paris Plump Ambition Hyaluron Lip Oil in Cherry Cherie
They found that miR-99 family including miR-99a/b and miR-100 was significantly downregulated on day 1 and returned to basal level on day 5
#NationalLipidDay #LipidProfile #CardioHealth #ClinicalDiagnostics #Lifescience #HORIBA To view or add a comment, sign in Part 2: The Science Behind Bitter Kolas Health Benefits Modern research is beginning to validate what traditional users have known for centuries
This article examines the compatibility of tirzepatide and protein shakes, addresses timing considerations, discusses optimal shake selection, and provides practical strategies for maintaining adequate protein intake while managing common gastrointestinal side effects during treatment
Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is characterized by hepatic steatosis without external causes (e.g., alcohol use, viral hepatitis, medications).[49] MASLD is associated with various metabolic disorders and has a bidirectional relationship with T2DM, with either disease predisposing to the other.[36] Current management guidance from the American Association for the Study of Liver Diseases emphasizes lifestyle modification and optimization of comorbidities (e.g., diabetes, obesity) while acknowledging only a handful of drug therapies with proven benefit, including GLP-1RAs.[50] In the phase 2 LEAN trial (n=26), liraglutide reduced steatosis, fibrosis, and histologic steatotic hepatitis in participants with non-alcoholic steatohepatitis.[13] In a larger study of participants with MASLD on semaglutide, steatotic hepatitis resolution was dose-dependent.[20] A study of 1,197 patients with metabolic dysfunction-associated steatohepatitis and fibrosis found nearly two-thirds (63.9%) had resolution of steatohepatitis without worsening fibrosis with weekly semaglutide 2.4mg, compared to only 34.25% in the placebo group.[19] In individuals without diabetes but with MASLD, a subgroup analysis of 26 MASLD studies identified that GLP-1RAs reduced hepatic steatosis while potentially improving liver enzymes.[14] While tirzepatide has been less studied for MASLD, it may reduce absolute liver fat.[5] Overall, GLP-1RAs may have use in patients with MASLD regardless of T2DM status, but their effects in patients with cirrhosis and significant fibrosis need further investigation
.webp)
